LY03017

Last updated
LY03017
Clinical data
Other namesLY-03017; LPM-526000133; LPM526000133
Routes of
administration 		Oral [1] [2]
Drug class Serotonin 5-HT2 receptor antagonist; Serotonin 5-HT2A receptor inverse agonist; Serotonin 5-HT2C receptor antagonist

LY03017, also known as LPM-526000133, is a serotonin 5-HT2 receptor antagonist which is under development for the treatment of schizophrenia. [1] [3] [2] It acts specifically as a dual serotonin 5-HT2A receptor inverse agonist and serotonin 5-HT2C receptor antagonist. [1] [3] [2] The drug is under development by Luye Pharma Group in China. [1] [3] As of December 2025, it is in phase 1 clinical trials. [1] [3] [2] The chemical structure of LY03017 does not yet appear to have been disclosed. [1]

See also

References

  1. 1 2 3 4 5 6 "LY 03017". AdisInsight. 31 December 2025. Retrieved 31 January 2026.
  2. 1 2 3 4 "LY-03017 Drug Profile". Ozmosi. 1 January 1900. Retrieved 31 January 2026.
  3. 1 2 3 4 "Delving into the Latest Updates on LPM526000133 with Synapse". Synapse. 24 January 2026. Retrieved 31 January 2026.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.